Compare Ecolab Inc. (ECL) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Illumina, Inc. — how do they compare? Ecolab Inc. trades at $282.05 (market cap $78.97B), while Illumina, Inc. trades at $271.25 (market cap $39.95B). The key difference: Ecolab Inc. is the larger of the two by market cap, and Ecolab Inc. pays a 1.04% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and Illumina, Inc. for 83 Days on average.
| ECL | ILMN | |
|---|---|---|
Market Cap | $78.97B | $39.95B |
Volume | 974,947 | 3,169,503 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $293.69 |
52-Week Low | $245.73 | $91.00 |
Typical Hold Time | 90 Days | 83 Days |
Enterprise Value | $87.75B | $41.31B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $278.10, down 0.97% on the day, with strong analyst support (78% buy ratings) and a $326.38 consensus price target suggesting 17% upside. The stock shows bullish technical signals with support at $275 and resistance at $279. Recent Q2 2026 earnings beat expectations with 9.7% sales growth, while the company maintains dividend aristocrat status with consistent payout increases.
ECL presents a compelling growth story with expanding high-tech and digital segments, though elevated valuation multiples (P/E 37.81) and rising debt from the CoolIT acquisition warrant caution. The essential nature of its hygiene and water management services provides defensive characteristics, while upcoming Q3 earnings on October 27 will be critical for validating growth trajectory.
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
